Potential of Tyrosine Kinase Receptor TIE-1 as Novel Therapeutic Target in High-PI3K-Expressing Ovarian Cancer.

Zhang, Xuewei; Ishibashi, Masumi; Kitatani, Kazuyuki; Shigeta, Shogo; Tokunaga, Hideki; Toyoshima, Masafumi; Shimada, Muneaki; Yaegashi, Nobuo

Zhang, Xuewei; Ishibashi, Masumi; Kitatani, Kazuyuki; Shigeta, Shogo; Tokunaga, Hideki; Toyoshima, Masafumi; Shimada, Muneaki; Yaegashi, Nobuo.

Afiliación

Zhang X; Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Tohoku University, Sendai 980-8577, Japan.
Ishibashi M; Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Tohoku University, Sendai 980-8577, Japan.
Kitatani K; Cancer Science Institute of Singapore, National University of Singapore, Singapore 119077, Singapore.
Shigeta S; Laboratory of Immunopharmacology, Faculty of Pharmaceutical Sciences, Setsunan University, Hirakata, Osaka 572-8508, Japan.
Tokunaga H; Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Tohoku University, Sendai 980-8577, Japan.
Toyoshima M; Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Tohoku University, Sendai 980-8577, Japan.
Shimada M; Department of Obstetrics and Gynecology, Japanese Red Cross Ishinomaki Hospital, Ishinomaki 986-8522, Japan.
Yaegashi N; Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Tohoku University, Sendai 980-8577, Japan.

Cancers (Basel) ; 12(6)2020 Jun 26.

Article en En | MEDLINE | ID: mdl-32604863

Palabras clave

PI3K; TIE-1; molecular targeted therapy; ovarian cancer

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2020 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google